Supplementary Table 1. Correlation of prevalence of EpCAM/CD49 with breast cancer prognosis (univariate analysis).
| No. (%) | DFS | OS | |||
|---|---|---|---|---|---|
| Log-rank | p-value | Log-rank | p-value | ||
| EpCAM-/CD49f+ (%) | 150 | 6.876 | 0.009 | 11.814 | 0.001 |
| 0 | 103 (68.7) | ||||
| >0 | 47 (31.3) | ||||
| EpCAM+/CD49f- (%) | 150 | 1.659 | 0.198 | 0.233 | 0.629 |
| 0 | 94 (62.7) | ||||
| >0 | 56 (37.3) | ||||
| EpCAM+/CD49f+ (%) | 150 | 2.761 | 0.097 | 2.754 | 0.097 |
| 0 | 110 (73.3) | ||||
| >0 | 40 (26.7) | ||||
| EpCAM-/CD49f- (%) | 150 | 0.631 | 0.427 | 0.180 | 0.671 |
| 0 | 26 (17.3) | ||||
| >0 | 124 (82.7) | ||||
EpCAM=epithelial cell adhesion molecule; DFS=disease-free survival; OS=overall survival.